Repatha
Early Treatment With Repatha Lowered Incidence of CV Death, Other Events
Long-term treatment with evolocumab in adults with atherosclerosis lowered the incidence of major cardiovascular ...
SEPTEMBER 8, 2022
Amgen Lowers List Price for Repatha for Everyone
Effective Dec. 31, 2019, evolocumab will be distributed exclusively at the 60% lower list price of $5,850 per year ...
OCTOBER 24, 2019
Abarca, Amgen Bet on PCSK9 Outcomes
Innovative pharmacy benefits manager (PBM) Abarca has entered into an outcomes-based contract for the proprotein ...
APRIL 11, 2018
PBM Abarca Announces Outcomes-Based Contract for Amgen’s Evolocumab
Innovative PBM Abarca has entered into an outcomes-based contract for the PCSK9 inhibitor evolocumab with Amgen, ...
MARCH 9, 2018
New Indication Granted for Repatha for Wider Group of Patients: Adults with CVD
Repatha's indication had been limited to patients with homozygous familial hypercholesterolemia who require ...
DECEMBER 2, 2017
Most Insurers Denying Claims for PCSK9 Inhibitors
PCSK9 inhibitors, such as Repatha and Praluent have been shown to reduce low-density lipoprotein by 60% and ...
NOVEMBER 29, 2017
Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs
Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.
MARCH 24, 2016
Evolocumab Reduces LDL in Patients With Diabetes
Will PCSK9 drug inhibitors make a difference in how we treat type 2 diabetes?
FEBRUARY 26, 2016
